Antares Pharma, a pharma product development company, has appointed Paul Wotton as its new president and CEO.
Subscribe to our email newsletter
Dr Wotton previously served as president and COO. Concurrently, Jack Stover has resigned as both CEO and vice chairman of the board of directors.
Dr Wotton joined Antares Pharma as president and COO in July 2008, having over 20 years of experience in the pharmaceutical industry with both large and specialty pharma companies. Previously, Dr Wotton served as CEO of Topigen Pharmaceuticals.
Prior to joining Topigen, Dr Wotton served as head of global business development at SkyePharma and also held senior level positions at Eurand International, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. He is a member of the board of directors of Antares Pharma and the Genaera Corporation.
Leonard Jacob, chairman of Antares Pharma, said: The board of directors is confident that Paul’s vast experience in clinical and business development is the right skill set necessary to achieve success in executing on Antares’s growth strategy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.